Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to support ADC development and manufacturing

Mumbai-based Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma, and Japan-based Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical manufacturing services and platform technologies, have announced a strategic collaboration.

Under this collaboration, Piramal will refer applicable customers seeking antibody drug conjugate (ADC) manufacturing technology to Aji Bio-Pharma and AJICAP™. Aji Bio-Pharma will refer Piramal to customers as a potential CDMO for manufacturing products using AJICAP™ technology, supporting their programs across development and manufacturing.

Following the execution of this agreement, Piramal and Ajinomoto will enter into a separate Material Transfer Agreement (MTA) to allow the transfer of technology between companies. The MTA will equip Piramal with the expertise, capabilities, and personnel for it to manufacture AJICAP™-based products with precision and speed.

With a global network of state-of-the-art facilities, Piramal has developed hundreds of ADCs, completed thousands of batches, and currently manufactures multiple commercial ADCs. Ongoing expansions are increasing Piramal's commercial-scale ADC capacity.